Acalabrutinib study with best supportive care in participants hospitalized with COVID-19

Trial Identifier: D822FC00005
Sponsor: AcertaPharma
Collaborator:
Astrazeneca
NCTID:: NCT04497948
Start Date: September 2020
Primary Completion Date: November 2020
Study Completion Date: November 2020
Condition: COVID-19 Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English version
Portuguese Translation

Trial Locations

Country Location
Brazil Porto Alegre, Brazil, 90035-003
Brazil Ribeirão Preto, Brazil, 14051-140
Brazil Sao Paulo, Brazil, 01323-903
Brazil Sao Paulo, Brazil, 01321-001
United States of America, CA Fullerton, CA, United States of America, 92835
United States of America, MD Baltimore, MD, United States of America, 21287
United States of America, MN Rochester, MN, United States of America, 55902
United States of America, NC CHAPEL HILL, NC, United States of America, 27599-7081
United States of America, PA Philadelphia, PA, United States of America, 19140